NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine ...

BOSTON, March 3, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the company's product development activities. "Working with our partner Intrexon Corporation, we made extensive progress in 2013 toward expanding...

BOSTON, Jan. 8, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2014 at 11:30 a.m. PT at The Westin St. Francis in San Francisco, CA. To access a live audio webca...

BOSTON, Dec. 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral...

BOSTON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of its previously announced public offering of 14,300,000 shares of its common stock at a public offering price of $3.50 per share. All of the shares in the offering are being sold by ZIOPHARM. The offering is expected to close on October 29,...

BOSTON, Oct. 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to commence an underwritten public offering of $50,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM. J.P. Morgan Securities LLC will act as sole book-running manager for the ...

BOSTON and GERMANTOWN, Md., Oct. 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of a preclinical study demonstrating the potential for...

BOSTON and GERMANTOWN, Md., Oct. 17, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced scheduled poster presentations at the 2013 AACR-NCI-EORTC International...

BOSTON, Sept. 20, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at BioCentury's NewsMakers in the Biotech Industry Conference on Friday, September 27th, 2013 at 8:30 a.m. ET at The Millennium Broadway Hotel in New York City. To access a live...

BOSTON, July 2, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 8th Annual JMP Securities Healthcare Conference on Tuesday, July 9th, 2013 at 2:30 p.m. ET at The St. Regis Hotel in New York City. To access a live webcast of the presenta...